Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Clicks: 401
ID: 116578
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #9 of 85 articles by views in inflammatory bowel diseases

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Sustaining clinical remission is an important treatment goal in moderate-to-severe UC. This post hoc exploratory analysis assessed the long-term efficacy of vedolizumab in the subset of patients with UC in the GEMINI 1 study who were in clinical remission ...
Reference Key
o’byrne2019inflammatorysustained Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Brian G Feagan, Stefan Schreiber, Douglas C Wolf, Jeffrey L Axler, Arpeat Kaviya, Alexandra James, Rebecca I Curtis, Parnia Geransar, Andreas Stallmach, Robert Ehehalt, Bernd Bokemeyer, Javaria Mona Khalid, Sharon O’Byrne;Brian G Feagan;Stefan Schreiber;Douglas C Wolf;Jeffrey L Axler;Arpeat Kaviya;Alexandra James;Rebecca I Curtis;Parnia Geransar;Andreas Stallmach;Robert Ehehalt;Bernd Bokemeyer;Javaria Mona Khalid;Sharon O’Byrne;
Journal inflammatory bowel diseases
Year 2019
DOI
10.1093/ibd/izy323
URL
http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6499937/
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.